Neural crest transcription factor Sox10 is preferentially expressed in triple-negative and metaplastic breast carcinomas

Ashley M Cimino-Mathews, Andrea P. Subhawong, Hillary Elwood, Hind Nassar Warzecha, Rajni Sharma, Ben Ho Park, Janis M Taube, Peter B Illei, Pedram Argani

Research output: Contribution to journalArticle

Abstract

The transcription factor Sox10 mediates the differentiation of neural crest-derived cells, and Sox10 labeling by immunohistochemistry (IHC) is used clinically primarily to support the diagnosis of melanoma. Sox10 expression by IHC has been previously documented in benign breast myoepithelial cells but not in breast carcinomas. Here, we report the first systematic study of Sox10 expression in invasive ductal carcinomas subclassified by IHC-defined molecular subtype (100 cases), as well as in 24 cases of ductal carcinoma in situ and 44 mammary fibroepithelial neoplasms. Tissue microarrays containing 168 primary breast tumors were subjected to IHC for Sox10. The extent of nuclear Sox10 labeling was scored by percentage labeling as follows: 0 (0%), 1+ (1%-25%), 2+ (25%-50%), 3+ (50%-75%), and 4+ (>75%). Overall, 40 (40%) of 100 invasive breast carcinomas demonstrated Sox10 immunoreactivity, which was seen primarily in the basal-like, unclassified triple-negative, and metaplastic carcinomas. Sox10 labeling was seen in 66% (38/58) of the basal-like, unclassified triple-negative, and metaplastic carcinomas as compared with 5% (2/42) of the luminal A, luminal B, and Her-2 carcinomas (P

Original languageEnglish (US)
Pages (from-to)959-965
Number of pages7
JournalHuman Pathology
Volume44
Issue number6
DOIs
StatePublished - Jun 2013

    Fingerprint

Keywords

  • Basal-like carcinoma
  • Breast carcinoma
  • Metaplastic carcinoma
  • Myoepithelial
  • Sox10

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this